DFM Platform

Ouvry SAS: CBRN Personal Protection and Decontamination Analysis

26 pages · PDF · 20 December 2025 · Licensed single-user copy, watermarked to the buyer

Tactical Biotechnology, Human Enhancement & MedTech France

Cover of the DFM report “Ouvry SAS: CBRN Personal Protection and Decontamination Analysis” — Defence-Finance Analysis, 26-page PDF

€299 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment

One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).

About this report

Ouvry SAS is a French defence SME pioneering advanced CBRN (Chemical, Biological, Radiological and Nuclear) protective equipment. From its base in Lyon, the company has quietly become a linchpin in Europe’s CBRN defense ecosystem.

Ouvry’s core value lies in its ability to deliver state-of-the-art personal protective systems – from air-permeable combat suits to rapid decontamination kits – that enable military and security forces to operate safely in toxic environments.

Key questions this report answers

Who it's for

Investors screening Ouvry SAS, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.

Related reports

Methodology, format & delivery

DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (20 December 2025). You receive a 26-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.

Related on DFM

More Tactical reports · Biotechnology, Human Enhancement & MedTech · All reports

Prefer unlimited access?

Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →

Get the full report — €299 →